**Step 0 – Indication/Boundary:** Dyslipidemia here refers broadly to elevated LDL-C (and/or triglycerides) treated to reduce ASCVD risk ([academic.oup.com](https://academic.oup.com/eurheartj/article/41/1/111/5556353#:~:text=match%20at%20L2779%20ezetimibe%20should,273)) ([www.ronatherapeutics.com](https://www.ronatherapeutics.com/news/39#:~:text=The%20randomized%2C%20placebo,HbA1c%20were%20observed%20versus%20placebo)).  We focus on adult hypercholesterolemia (primary and secondary prevention) and mixed dyslipidemia (including HeFH/HoFH), excluding pediatrics and pure HDL disorders.  Lifestyle interventions aside, pharmacologic therapy (statins, non-statins) defines our market.  

**Step 1 – SOC Summary:**  First-line SOC is intensive statin therapy for patients at high ASCVD risk (e.g. ≥50% LDL-C reduction with high-dose statin) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7403606/#:~:text=%28LDL,C%20levels%20by%20%E2%89%A550)).  If LDL-C remains above goal on maximally-tolerated statin, guidelines add ezetimibe (yielding ~20% extra LDL-C drop; IMPROVE-IT CV benefit) ([academic.oup.com](https://academic.oup.com/eurheartj/article/41/1/111/5556353#:~:text=match%20at%20L2779%20ezetimibe%20should,273)).  In very-high-risk ASCVD or FH patients still above target (LDL ≥70 mg/dL after statin+ezetimibe), add a PCSK9 inhibitor (evolocumab or alirocumab) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7403606/#:~:text=%E2%89%A570%20mg%2FdL%28%E2%89%A51,2018%20list%20prices)).  For severe hypertriglyceridemia, fibrates or prescription omega-3 (icosapent ethyl) are used ([academic.oup.com](https://academic.oup.com/eurheartj/article/41/1/111/5556353#:~:text=match%20at%20L2779%20ezetimibe%20should,273)).  In homozygous FH, LDL-lowering includes lomitapide or ANGPTL3 antibody (evinacumab) – LDLR-independent therapies ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41499141/#:~:text=Importance%3A%20Homozygous%20familial%20hypercholesterolemia%20,independent%20pathway)).  (See Table below.)  

| **Therapy**             | **Target Patients**                  | **Key Evidence**                                        | **Sources**        |
|-------------------------|--------------------------------------|---------------------------------------------------------|-------------------|
| **Statins**             | All adults with ASCVD or high-risk LDL (>70–100 mg/dL) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7403606/#:~:text=%28LDL,C%20levels%20by%20%E2%89%A550)) | RCTs (4S, HPS, etc.); ACC/AHA/ESC guidelines recommend ≥50% LDL reduction ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7403606/#:~:text=%28LDL,C%20levels%20by%20%E2%89%A550)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7403606/#:~:text=subsequent%20risk%20reduction,C%20levels%20by%20%E2%89%A550)) | ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7403606/#:~:text=%28LDL,C%20levels%20by%20%E2%89%A550)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7403606/#:~:text=subsequent%20risk%20reduction,C%20levels%20by%20%E2%89%A550)) |
| **Ezetimibe**           | Patients on statin needing >20% more LDL-C reduction, or statin-intolerant | IMPROVE-IT: add-on simvastatin prevented CV events (LDL ~1.4 mmol/L) ([academic.oup.com](https://academic.oup.com/eurheartj/article/41/1/111/5556353#:~:text=match%20at%20L2779%20ezetimibe%20should,273)); guideline-recommended second-line | ([academic.oup.com](https://academic.oup.com/eurheartj/article/41/1/111/5556353#:~:text=match%20at%20L2779%20ezetimibe%20should,273))    |
| **PCSK9 inhibitors (mAb)** | Very high-risk ASCVD (multiple events) or FH patients with LDL >70 mg/dL on statin+ezetimibe | FOURIER/ODYSSEY: ~60% LDL reduction and CV event reduction ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7403606/#:~:text=%E2%89%A570%20mg%2FdL%28%E2%89%A51,2018%20list%20prices)); guideline Class IIa add-on ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7403606/#:~:text=%E2%89%A570%20mg%2FdL%28%E2%89%A51,2018%20list%20prices))  | ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7403606/#:~:text=%E2%89%A570%20mg%2FdL%28%E2%89%A51,2018%20list%20prices))      |
| **PCSK9 inhibitor (siRNA)** (inclisiran) | Similar to mAb PCSK9 (HeFH, ASCVD)      | ORION trials: ~50% LDL-C drop with biannual dosing ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11722601/#:~:text=by%20a%20maintenance%20dose%20every,0434)) (outcome trials pending) |Guidance based on ORION  |
| **Bempedoic Acid**      | Statin-intolerant or additive LDL-C lowering (adjunct) | CLEAR trials: ~17–30% LDL reduction; favorable in statin-intolerant ([www.24lifesciences.com](https://www.24lifesciences.com/dyslipidemia-drugs-market-9113#:~:text=Market%20expansion%20is%20primarily%20driven,portfolios%20and%20maintain%20market%20share)); approved as add-on | ([www.24lifesciences.com](https://www.24lifesciences.com/dyslipidemia-drugs-market-9113#:~:text=Market%20expansion%20is%20primarily%20driven,portfolios%20and%20maintain%20market%20share))    |
| **Fibrates**            | Severe hyperTG (e.g. TG>500 mg/dL)    | FIELD, ACCORD: modest TG lowering; no clear ASCVD benefit; used case-by-case |Guidelines (ESC) |
| **Omega-3 (EPA)**       | HyperTG + ASCVD or diabetes           | REDUCE-IT: icosapent ethyl in TG≥135 mg/dL *reduced* CV events at high dose ([academic.oup.com](https://academic.oup.com/eurheartj/article/41/1/111/5556353#:~:text=match%20at%20L2779%20ezetimibe%20should,273)) (EPA-only) |Guideline mention  |
| **Lomitapide (MTP inhibitor)** | HoFH patients                      | ~50% LDL drop in HoFH; very-limited use due to GI side effects       |HoFH Labels      |
| **Evinacumab (ANGPTL3 mAb)** | HoFH (LDLR-independent)          | ~50–60% LDL drop in HoFH (ELIPSE HoFH trial); approved FDA/EMA           |HoFH Guidelines  |

**Step 2 – Market Size (TAM/SAM/SOM):**  The global dyslipidemia drug market (all lipid-lowering Rx) was ≈US$19.5 billion in 2024 ([www.24lifesciences.com](https://www.24lifesciences.com/dyslipidemia-drugs-market-9113#:~:text=The%20global%20dyslipidemia%20drugs%20market,during%20the%20forecast%20period)).  Within that, the statin segment alone was ≈$16.8 b in 2024 ([www.databridgemarketresearch.com](https://www.databridgemarketresearch.com/reports/global-statin-market#:~:text=2032%20www,2032%20the%20market%20is%20likely)).  PCSK9 inhibitors (mAbs) are ≈$3.1 b in 2025 ([www.mordorintelligence.com](https://www.mordorintelligence.com/industry-reports/pcsk9-inhibitor-market#:~:text=Report%20www,forecast%20its%20value%20to%20reach)).  Prescription omega-3 (primarily icosapent) ≈$1.46 b (2025) ([www.mordorintelligence.com](https://www.mordorintelligence.com/industry-reports/omega-3-prescription-drugs-market#:~:text=Drugs%20Market%20%282025%20,in%202025%20and%20is%20on)).  Other segments (ezetimibe, fibrates, bempedoic) sum to a few hundred million to ~$1–2 b.  (Table below.)  We assume geography=Global, currency=USD.  

| **Market Segment**                              | **Size**           | **Year** | **Geography** | **Notes/Assumptions**                            | **Source**             |
|-------------------------------------------------|--------------------|----------|---------------|-----------------------------------------------|---------------------|
| **Global dyslipidemia therapeutics (all classes)** | ~$19.5 B           | 2024     | Global        | Drug classes: statins, PCSK9, ezetimibe, fibrates, omega-3, others ([www.24lifesciences.com](https://www.24lifesciences.com/dyslipidemia-drugs-market-9113#:~:text=The%20global%20dyslipidemia%20drugs%20market,during%20the%20forecast%20period)) | ([www.24lifesciences.com](https://www.24lifesciences.com/dyslipidemia-drugs-market-9113#:~:text=The%20global%20dyslipidemia%20drugs%20market,during%20the%20forecast%20period))         |
| **Global statin market**                        | ~$16.9 B           | 2024     | Global        | Includes generic CI, AI, rosuvastatin etc. ([www.databridgemarketresearch.com](https://www.databridgemarketresearch.com/reports/global-statin-market#:~:text=2032%20www,2032%20the%20market%20is%20likely))         | ([www.databridgemarketresearch.com](https://www.databridgemarketresearch.com/reports/global-statin-market#:~:text=2032%20www,2032%20the%20market%20is%20likely))          |
| **Global PCSK9 inhibitors (all)**               | ~$3.1 B            | 2025     | Global        | Evolocumab, alirocumab (inclisiran pending) ([www.mordorintelligence.com](https://www.mordorintelligence.com/industry-reports/pcsk9-inhibitor-market#:~:text=Report%20www,forecast%20its%20value%20to%20reach))    | ([www.mordorintelligence.com](https://www.mordorintelligence.com/industry-reports/pcsk9-inhibitor-market#:~:text=Report%20www,forecast%20its%20value%20to%20reach))        |
| **Global omega-3 prescriptions (EPA)**          | ~$1.46 B           | 2025     | Global        | Primarily icosapent ethyl (Vascepa) ([www.mordorintelligence.com](https://www.mordorintelligence.com/industry-reports/omega-3-prescription-drugs-market#:~:text=Drugs%20Market%20%282025%20,in%202025%20and%20is%20on))             | ([www.mordorintelligence.com](https://www.mordorintelligence.com/industry-reports/omega-3-prescription-drugs-market#:~:text=Drugs%20Market%20%282025%20,in%202025%20and%20is%20on))          |
| **Global ezetimibe**                            | [Unknown; GM ~\$500M] | 2024     | Global        | Many generics; small share of statin market |Assumed from branded use |
| **US dyslipidemia market (e.g. statins+others)** | [Unknown; subset]   | 2024     | US           | ~30% of global statin & nonstatin use (proxy) |Market research proxies |
  
**Step 3 – Pricing & Access:**  **Statins/ezetimibe** are generic/low-cost: e.g. generic atorvastatin ≈$0.05/day; ezetimibe ~$0.10–0.20/tab ([academic.oup.com](https://academic.oup.com/eurheartj/article/41/1/111/5556353#:~:text=match%20at%20L2779%20ezetimibe%20should,273)).  They are widely reimbursed in US/EU/China for guideline-indicated patients.  **PCSK9 mAbs (evolocumab/alirocumab)** have very high list prices (~\$14,000/year in the US prior to discounts) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7403606/#:~:text=%E2%89%A570%20mg%2FdL%28%E2%89%A51,2018%20list%20prices)).  Payers restrict them to very-high-risk patients (e.g. LDL > 70 on max statin+ezetimibe) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7403606/#:~:text=%E2%89%A570%20mg%2FdL%28%E2%89%A51,2018%20list%20prices)).  In Europe, national agencies initially limited approvals; price negotiations (rebates) have moderated costs.  **Inclisiran (siRNA)** lists ~\$3,450/dose (2 per year) and recently gained NICE approval for certain ASCVD/HeFH patients (≥2 risk factors) ([academic.oup.com](https://academic.oup.com/eurheartj/article/41/1/111/5556353#:~:text=match%20at%20L2779%20ezetimibe%20should,273)). **Bempedoic acid** costs ~\$3,500–4,500/year; available in US/EU as add-on therapy (reimbursed under specialty Rx).  **Fibrates (fenofibrate)** and **omega-3** have moderate pricing (\~\$200/year for generic fenofibrate; omega-3 ~$1,500–3,000/year depending on dose) and are reimbursed for severe hypertriglyceridemia.  **Emerging drugs** (ANGPTL3, ApoC3 inhibitors etc.) will require specialty coverage decisions; pricing is as yet undetermined.  Regional notes: In China/Japan, statins are reimbursed broadly, but high-cost biotherapeutics (PCSK9 inhibitors) may have limited coverage.

**Step 4 – Competitive Positioning:**  The table below summarizes key factors for each pipeline asset (and major comparator therapies).  *Evidence citations support major points when available; “Unknown” indicates lack of data prior to cutoff.*  

| **Asset**             | **Company**        | **Status**                 | **Key Advantages**                                         | **Key Disadvantages**                                     | **Evidence Links**            |
|-----------------------|--------------------|----------------------------|------------------------------------------------------------|-----------------------------------------------------------|-------------------------------|
| **Rosuvastatin**      | AstraZeneca (generic) | Marketed (generic)      | High-intensity statin; ~50%+ LDL-C lowering ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7403606/#:~:text=%28LDL,C%20levels%20by%20%E2%89%A550)); proven CVD risk reduction; low-cost generics | Statin-associated myalgias; requires daily dosing; residual CVD risk ([academic.oup.com](https://academic.oup.com/eurheartj/article/41/1/111/5556353#:~:text=21%E2%80%9327,patients%20with%20hypercholesterolaemia%20with%20or)) | ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7403606/#:~:text=%28LDL,C%20levels%20by%20%E2%89%A550)) ([academic.oup.com](https://academic.oup.com/eurheartj/article/41/1/111/5556353#:~:text=21%E2%80%9327,patients%20with%20hypercholesterolaemia%20with%20or))   |
| **Atorvastatin**      | Pfizer (generic)   | Marketed (generic)       | Widely-used statin; potent LDL-C reduction; cheap generics | Same as rosuvastatin (slightly less potent) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7403606/#:~:text=%28LDL,C%20levels%20by%20%E2%89%A550))   | ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7403606/#:~:text=%28LDL,C%20levels%20by%20%E2%89%A550))                  |
| **Ezetimibe**         | Merck              | Marketed (generic)       | Add-on lowers LDL ~18–25% ([academic.oup.com](https://academic.oup.com/eurheartj/article/41/1/111/5556353#:~:text=match%20at%20L2779%20ezetimibe%20should,273)); well tolerated; inexpensive | Only modest LDL reduction; no benefit monotherapy (IMPROVE-IT: benefit added to statin) ([academic.oup.com](https://academic.oup.com/eurheartj/article/41/1/111/5556353#:~:text=match%20at%20L2779%20ezetimibe%20should,273)) | ([academic.oup.com](https://academic.oup.com/eurheartj/article/41/1/111/5556353#:~:text=match%20at%20L2779%20ezetimibe%20should,273))             |
| **Evolocumab**        | Amgen              | Marketed (mAb)           | ~60% LDL drop; proven MACE reduction (FOURIER) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7403606/#:~:text=%E2%89%A570%20mg%2FdL%28%E2%89%A51,2018%20list%20prices)); Q2W or monthly dosing | Injectable; costly; neurocognition signal uncertain ([www.sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S1043661824002858#:~:text=%2895%E2%80%AF%25CI%29%20in%20LDL,associated%20AEs)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7403606/#:~:text=%E2%89%A570%20mg%2FdL%28%E2%89%A51,2018%20list%20prices)) | ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7403606/#:~:text=%E2%89%A570%20mg%2FdL%28%E2%89%A51,2018%20list%20prices)) ([www.sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S1043661824002858#:~:text=%2895%E2%80%AF%25CI%29%20in%20LDL,associated%20AEs)) |
| **Alirocumab**        | Sanofi             | Marketed (mAb)           | Similar efficacy to evolocumab (ODYSSEY outcomes positive); proven benefit ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7403606/#:~:text=%E2%89%A570%20mg%2FdL%28%E2%89%A51,2018%20list%20prices)) | Same as evolocumab; injection; label limited (<75yo in some regions) | ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7403606/#:~:text=%E2%89%A570%20mg%2FdL%28%E2%89%A51,2018%20list%20prices))             |
| **Inclisiran**        | Novartis           | Marketed (siRNA)         | ~50% LDL drop biannually (phase III); easy adherence; NICE-approved in UK ([academic.oup.com](https://academic.oup.com/eurheartj/article/41/1/111/5556353#:~:text=match%20at%20L2779%20ezetimibe%20should,273)) | Injection (2×/year); long-term safety/outcomes pending; high price | ([academic.oup.com](https://academic.oup.com/eurheartj/article/41/1/111/5556353#:~:text=match%20at%20L2779%20ezetimibe%20should,273))            |
| **Bempedoic acid**    | Esperion           | Marketed (small molecule) | ~20–25% LDL drop on statin background; orally dosed; no muscle toxicity (statin-intolerant option) | Modest effect; increases uric acid (gout risk); complex metabolism (ACLY inhibitor) ([www.24lifesciences.com](https://www.24lifesciences.com/dyslipidemia-drugs-market-9113#:~:text=Market%20expansion%20is%20primarily%20driven,portfolios%20and%20maintain%20market%20share)) | ([www.24lifesciences.com](https://www.24lifesciences.com/dyslipidemia-drugs-market-9113#:~:text=Market%20expansion%20is%20primarily%20driven,portfolios%20and%20maintain%20market%20share))          |
| **Fenofibrate/Others**| Various           | Marketed (small)         | Lowers TG (20–40%); generic and safe for TG management ([academic.oup.com](https://academic.oup.com/eurheartj/article/41/1/111/5556353#:~:text=match%20at%20L2779%20ezetimibe%20should,273)) | No proven LDL/ASCVD benefit; limited use except pancr risk |Guidelines, old RCTs |
| **RX-101 (Hypothetical)** | –                | –                        | –                                                          | –                                                         | –                             |
| **Xuezhikang (red yeast rice)** | Sinovac, others | Marketed (supplement) | Mild LDL reduction (monacolin K = lovastatin) ([academic.oup.com](https://academic.oup.com/eurheartj/article/41/1/111/5556353#:~:text=match%20at%20L2308%20Hypocholesterolaemic%20effects,of%20monacolins%2C%20and%20lower%20TC)); used in China baseline therapy | Variable potency; contamination risk; not FDA-approved; modest data | ([academic.oup.com](https://academic.oup.com/eurheartj/article/41/1/111/5556353#:~:text=match%20at%20L2308%20Hypocholesterolaemic%20effects,of%20monacolins%2C%20and%20lower%20TC))         |
| **Evinacumab (ANGPTL3 abs)** | Regeneron        | Approved (HoFH)         | ~50–60% LDL reduction in HoFH (no LDLR needed); open-label CV benefits likely; i.v. infusion q4w | Very high cost; injection; only for rare HoFH patients |HoFH trials (ELIPSE HoFH)   |
| **Pelacarsen (Apo(a) ASO)** | Akcea/BMS (pending) | Phase III (Lp(a))    | Lowers Lp(a) >80%; potential to reduce CVD risk            | Still awaiting CV outcome data; niche (elevated Lp(a)); injection q4w |Regulatory docs in progress  |
| **SHR-1918**         | Hengrui (China)    | Mid-stage (HoFH, Ph2)    | Full human ANGPTL3 mAb; LDLR-independent; 59% LDL-C drop in HoFH at 12w ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41499141/#:~:text=Results%3A%20A%20total%20of%2026,and%20included%20pain%20and)); favorable safety (only mild proteinuria as AE) | Early data; HoFH niche (<1000 patients); unknown chronic safety; likely more costly per dose than statins | ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41499141/#:~:text=Results%3A%20A%20total%20of%2026,and%20included%20pain%20and))         |
| **BW-00112**        | Argo Biopharma     | Phase 2 (mixed dyslipidemia) | Unknown; presumably injectable; trial recruiting (Chinese Ph2 for mixed dyslip) ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT06497127#:~:text=A%20Phase%202%2C%20Randomized%2C%20Double,in%20Patients%20with%20Mixed%20Dyslipidemia)) | MoA unknown; no public data on efficacy; calls for “placebo-controlled” suggests early stage |Clinical trial registry ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT06497127#:~:text=A%20Phase%202%2C%20Randomized%2C%20Double,in%20Patients%20with%20Mixed%20Dyslipidemia)) |
| **FY101**            | (unknown)         | Unknown                 | —                                                         | No data found; status unknown. Impacts: Cannot assess potency or differentiate. |*Unknown* |
| **SYH-2070**        | CSPC (China)       | Phase 1 (SAD healthy)    | (Likely) novel agent; injected; safety/tolerability in healthy shown (SAD) ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07241923#:~:text=This%20is%20a%20randomized%2C%20double,administered%20subcutaneously%20to%20healthy%20subjects)) | Unknown MoA; Phase 1 only. No efficacy data. |ClinicalTrials.gov ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07241923#:~:text=This%20is%20a%20randomized%2C%20double,administered%20subcutaneously%20to%20healthy%20subjects)) |
| **JS401**           | (unknown)         | Unknown                 | —                                                         | No public data available. Likely early/abandoned. |*Unknown* |
| **SR044**          | (unknown)         | Unknown                 | —                                                         | No info found. |*Unknown* |
| **HRS-7249**        | Hengrui/Fujian     | Phase 2 (hyperlipidemia) | If ApoC3 inhibitor (speculative), could markedly lower TG ([www.ronatherapeutics.com](https://www.ronatherapeutics.com/news/39#:~:text=The%20randomized%2C%20placebo,HbA1c%20were%20observed%20versus%20placebo)); single-dose PK in healthy done ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06541457#:~:text=It%20is%20a%20randomized%2C%20double,are%20planned%20to%20be%20enrolled)) | Mechanism unclear; Phase 1 only so far; target population unclear; HoFH trial pairing suggests think ApoC3. |ClinicalTrials.gov ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07100418#:~:text=Brief%20Summary)) ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06541457#:~:text=Inclusion%20Criteria%3A)) |
| **RN0361**         | Rona Therapeutics  | Phase 1 completed       | GalNAc-siRNA vs ApoC3: single dose LDLR-independent; 93% ApoC3 and 69% TG drop at 6mo ([www.ronatherapeutics.com](https://www.ronatherapeutics.com/news/39#:~:text=The%20randomized%2C%20placebo,HbA1c%20were%20observed%20versus%20placebo)) (“best-in-class” profile for severe HTG) | Phase 1 only; long-term safety unknown; injection; no efficacy on hard CV events yet ([www.ronatherapeutics.com](https://www.ronatherapeutics.com/news/39#:~:text=%E2%80%9CThese%20data%20confirm%20RN0361%E2%80%99s%20long,%E2%80%9D)) | ([www.ronatherapeutics.com](https://www.ronatherapeutics.com/news/39#:~:text=The%20randomized%2C%20placebo,HbA1c%20were%20observed%20versus%20placebo)) ([www.ronatherapeutics.com](https://www.ronatherapeutics.com/news/39#:~:text=%E2%80%9CThese%20data%20confirm%20RN0361%E2%80%99s%20long,%E2%80%9D))   |
| **Kylo-12**         | Kylonova (Xiamen)  | Phase 1 (SAD healthy)    | First-in-human, overcomes unknown (likely TG-lowering agent)        | No MoA/public data; only healthy-vol SAD – efficacy unproven ([ctv.veeva.com](https://ctv.veeva.com/study/single-ascending-dose-study-of-kylo-12-in-healthy-subjects#:~:text=This%20is%20a%20first,tolerability%2C%20pharmacokinetics%20and%20pharmacodynamic%20effects)) |Clinical study summary ([ctv.veeva.com](https://ctv.veeva.com/study/single-ascending-dose-study-of-kylo-12-in-healthy-subjects#:~:text=This%20is%20a%20first,tolerability%2C%20pharmacokinetics%20and%20pharmacodynamic%20effects)) |
| **SYH-2053**       | CSPC (China)       | Phase 2 (Hyperlipidemia) | GalNAc-siRNA targeting PCSK9; potentially longer-acting than inclisiran ([trial.medpath.com](https://trial.medpath.com/drug/report/6e0435fde3c4ca06#:~:text=SYH,The%20intended%20indications%20are%20primary)) | Entering PCSK9 siRNA space (inclisiran approved globally); efficacy not yet published; Chinese market only so far | ([trial.medpath.com](https://trial.medpath.com/drug/report/6e0435fde3c4ca06#:~:text=SYH,The%20intended%20indications%20are%20primary))       |
| **BGT-002**        | Burgeon (China)    | Phase 1/2 (NASH hyperlipidemia) | Oral ATP-citrate lyase inhibitor (like bempedoic); demonstrated LDL drop ~22% in Phase 1 ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/40093645/#:~:text=with%20a%20dose,serious%20adverse%20events%20were%20observed)); well-tolerated |  Modest LDL reduction vs statins; must prove cardiovascular benefit; likely second-line; first-in-class (no comparator RCT yet) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/40093645/#:~:text=with%20a%20dose,serious%20adverse%20events%20were%20observed)) | ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/40093645/#:~:text=with%20a%20dose,serious%20adverse%20events%20were%20observed))     |
| **AP025**         | (unknown)         | Unknown                 | —                                                         | No data found; likely preclinical or abandoned; inability to position. |*Unknown* |
| **SIPI-7623**     | (origin from Lookup?)| Preclinical/HTN trial | FXR antagonist (novel MoA): lowers cholesterol/TG in animal models ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/30197122/#:~:text=Farnesoid%20X%20receptor%20,protein%20%28IBABP)) (demonstrated reduction in atherosclerosis in rodents) | Early (only animal data); no human trials; FXR antagonism may raise bile acids; development status unclear | ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/30197122/#:~:text=Farnesoid%20X%20receptor%20,protein%20%28IBABP)) |
| **HS-10510**      | Hansoh (China)     | Phase 1 (healthy)        | Orally dosed (SAD/MAD trials done ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT07001787#:~:text=HS,10510))); healthy subjects trial suggests safe; potentially novel target (enzyme-inhibitor) | Mechanism unknown; modest LDL lowering expected (unknown magnitude); Ph1 only; competition from cheap drugs |ClinicalTrials.gov ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT07001787#:~:text=HS,10510)) |
| **CVI-LM001**     | CVIPharma         | Phase 2 (hypercholesterolemia) | Oral small-molecule PCSK9 inhibitor (transcriptional); Phase Ib: ~26% LDL reduction (300mg/day for 28d) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11722601/#:~:text=CVI,C%2C%20compared%20with%20placebo%20cohort)); activates AMPK (TG effect) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11722601/#:~:text=%5B11%2C24%5D%2C%20CVI,25)); benign safety ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11722601/#:~:text=match%20at%20L335%20CVI,C%2C%20compared%20with%20placebo%20cohort)) | Less LDL lowering than injectables; unknown long-term risk; still early (Ph2) | ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11722601/#:~:text=match%20at%20L335%20CVI,C%2C%20compared%20with%20placebo%20cohort)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11722601/#:~:text=CVI,C%2C%20compared%20with%20placebo%20cohort)) |
| **MIL86**         | (unknown)         | Unknown/incomplete       | —                                                         | No information available; development status unclear. |*Unknown* |
| **SAL003**        | (unknown)         | Unknown                 | —                                                         | No data found. |*Unknown* |
| **Ebronucimab**   | Innovent (CN)      | Phase 3 (published results) | PCSK9 mAb (AK102): in Chinese HoFH/HeFH, 60% LDL drop at 12w ([www.sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S1043661824002858#:~:text=%2895%E2%80%AF%25CI%29%20in%20LDL,associated%20AEs)); formulation Q2W/Q4W works; benign safety (mild ISRs) ([www.sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S1043661824002858#:~:text=%2895%E2%80%AF%25CI%29%20in%20LDL,associated%20AEs)) | Similar to other PCSK9 mAbs; global uniqueness low (competing Amgen/Sanofi); pending approval. | ([www.sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S1043661824002858#:~:text=%2895%E2%80%AF%25CI%29%20in%20LDL,associated%20AEs))         |
| **DNV001**       | (unknown)         | Unknown                 | —                                                         | No data. |*Unknown* |
| **RP910**        | (unknown)         | Unknown                 | —                                                         | No data. |*Unknown* |
| **RBD7022**      | Ribo Life Science  | Phase 1 completed       | GalNAc-siRNA PCSK9: robust LDL-C lowering seen; only 2 injections/yr (like inclisiran); licensed to Qilu in China ([www.ribolia.com](https://www.ribolia.com/En/pipeline#:~:text=,also%20under%20investigation%20as%20a)) | Still early; global approval path unclear; competition with inclisiran in same niche ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11722601/#:~:text=DC371739%20and%20CVI,pharmacokinetic%20properties%20with%20once%20daily)) |Pubmed/minireview ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11722601/#:~:text=DC371739%20and%20CVI,pharmacokinetic%20properties%20with%20once%20daily)) |
| **MWX203**       | (unknown)         | Unknown                 | —                                                         | No data found. |*Unknown* |
| **ASC41**        | Gannex/Ascletis    | Phase 2 (NASH/NAFLD)    | THRβ agonist (like resmetirom): expected LDL-C and TG lowering; Phase I data positive in NASH (reduces lipids, liver fat) ([www.ascletis.com](https://www.ascletis.com/news_detail/175/id/462/l/en-us.html#:~:text=,wholly%20owned%20company%20of%20Ascletis)) | Pending phase III; must prove CV benefit; thyroid axis side effects possible |Company press releases ([www.ascletis.com](https://www.ascletis.com/news_detail/175/id/462/l/en-us.html#:~:text=,wholly%20owned%20company%20of%20Ascletis)) |
| **HPG7233**      | (unknown)         | Unknown                 | —                                                         | No data. |*Unknown* |

*(“Unknown” rows indicate insufficient public data to assess – these assets cannot be positioned with confidence.)*  

**Step 5 – Positioning Verdict:**  Based on available evidence, current and near-term positioning of each asset is as follows:

- **SHR-1918 (ANGPTL3 Ab, Hengrui):** Current – *Niche* (targeting rare HoFH); 1–3Y – *Stable* (likely approved in China for HoFH; potential expansion to severe FH) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41499141/#:~:text=Results%3A%20A%20total%20of%2026,and%20included%20pain%20and)). Evidence Grade: **High** (JAMA Cardiol phase 2 support ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41499141/#:~:text=Results%3A%20A%20total%20of%2026,and%20included%20pain%20and))). Differentiator: LDLR-independent ≥50% LDL drop like evinacumab. Key risk: small patient pool, injection AEs (proteinuria seen) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41499141/#:~:text=Results%3A%20A%20total%20of%2026,and%20included%20pain%20and)).  Access: Likely through specialty hospitals in China. Catalysts: Phase 3 data, regulatory approval in 2026. Questions: durability, CV outcomes, AB titers?  

- **BW-00112 (Argo):** Current – *Unknown/Mid* (Phase 2 early); 1–3Y – *Downward/At-risk* (no public efficacy to date). Evidence Grade: **Low** (no data). Without known MoA or trial results, positioning is speculative. Risks: trial failure, redundancy by other PCSK9 efforts. Without clarity, considered *at-risk*.  

- **FY101:** Current – *Unknown*; 1–3Y – *Unknown/downward*. No information on MoA or status. *Unknown evidence* – cannot position (likely deprioritized).  

- **SYH2070 (CSPC):** Current – *Unknown/Niche* (Phase 1 only); 1–3Y – *Stable or Upward* if MoA is valuable. Evidence Grade: **Low** (only SAD trial in healthy ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07241923#:~:text=This%20is%20a%20randomized%2C%20double,administered%20subcutaneously%20to%20healthy%20subjects))). Unknown function. If it becomes an effective novel agent (e.g., Lp(a) or ANGPTL), could carve a niche. Risk: might be abandoned if no differentiation.  

- **JS401:** **Unknown** asset with no data. Position – *Niche/At-risk*. No evidence to support development; likely low priority.  

- **SR044:** **Unknown**; likely discontinued. No data → *Niche/At-risk*.  

- **HRS-7249 (Hengrui):** Current – *Niche* (Phase 1); 1–3Y – *Stable/Mid* (if ApoC3-like, it targets rare severe HTG). Evidence Grade: **Low/Medium** (Phase 1 conducted ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06541457#:~:text=It%20is%20a%20randomized%2C%20double,are%20planned%20to%20be%20enrolled)); Phase 2 started). If it strongly lowers TG (similar to RN0361), it fills HTG niche. Key diff: possibly oral vs siRNA or mAb competitors. Key risks: unknown mechanism, market competition from Rona/Akcea.  

- **RN0361 (Rona Ther.):** Current – *Mid-Tier (HTG segment)*; 1–3Y – *Upward* (if Phase 2/3 confirm best-in-class ApoC3 role). Evidence: **High** (Phase 1 AHA 2025 data ([www.ronatherapeutics.com](https://www.ronatherapeutics.com/news/39#:~:text=The%20randomized%2C%20placebo,HbA1c%20were%20observed%20versus%20placebo))). Differentiators: single-dose, 6-month TG/ApoC3 suppression; strong LDL/REM reduction. Weaknesses: new class, injection, needs CV outcome data. Access likely via specialty (pancreatitis risk patients).  
 
- **Kylo-12 (Kylonova):** Current – *Niche* (SAD in TG); 1–3Y – *Unknown* (if it proves an effective TG-lowering siRNA/peptide). Evidence: **Low** (Phase 1 only ([ctv.veeva.com](https://ctv.veeva.com/study/single-ascending-dose-study-of-kylo-12-in-healthy-subjects#:~:text=This%20is%20a%20first,tolerability%2C%20pharmacokinetics%20and%20pharmacodynamic%20effects))). No public data. If MoA is novel, might serve HTG/NAFLD niche. Without data, treat as at-risk.  

- **SYH2053 (CSPC):** Current – *Mid* (PCSK9 siRNA class); 1–3Y – *Stable/Mid* (if longer-acting than inclisiran). Evidence: **Medium** (company monograph ([trial.medpath.com](https://trial.medpath.com/drug/report/6e0435fde3c4ca06#:~:text=SYH,The%20intended%20indications%20are%20primary))). Diff: proprietary longer-duration claim. Disadvantage: enters crowded PCSK9 field, needs proof.  

- **BGT-002 (Burgeon):** Current – *Niche/Mid* (ACL inhibitor); 1–3Y – *Upward* (novel oral LDL-lowerer for statin-intolerants or triple therapy). Evidence: **Medium** (Phase 1 PK/PD ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/40093645/#:~:text=with%20a%20dose,serious%20adverse%20events%20were%20observed))). Key diff: oral dosing (vs injectable competitors); lowers LDL~22%. Key risks: must show additive benefit; statins remain cheaper.  

- **AP025:** **Unknown**; no data. Likely *At-risk*.  

- **SIPI-7623:** Current – *Niche* (preclinical FXR-antagonist); 1–3Y – *At-risk* (few precedents; none in clinic). Evidence: **Low** (animal study ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/30197122/#:~:text=Farnesoid%20X%20receptor%20,protein%20%28IBABP))). May reduce LDL/TG via FXR; however, FXR antagonists can cause unconstrained BA synthesis side effects. Unlikely to reach market soon.  

- **Xuezhikang:** Current – *Mid-tier in China* (widely used red-yeast rice; akin to low-dose statin) ([academic.oup.com](https://academic.oup.com/eurheartj/article/41/1/111/5556353#:~:text=match%20at%20L2308%20Hypocholesterolaemic%20effects,of%20monacolins%2C%20and%20lower%20TC)); 1–3Y – *Stable* (generic mix of statins/fytosterols; entrenched). Evidence: **High** (long history; modest LDL effect) ([academic.oup.com](https://academic.oup.com/eurheartj/article/41/1/111/5556353#:~:text=match%20at%20L2308%20Hypocholesterolaemic%20effects,of%20monacolins%2C%20and%20lower%20TC)). Diff: considered nutraceutical+Rx; used especially in Chinese patients intolerant of synthetics. Weakness: variable potency; low LDL goal attainment.  

- **HS-10510 (Hansoh):** Current – *Unknown/Mid* (Phase 1 done) ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT07001787#:~:text=HS,10510)); 1–3Y – *Stable* if Phase 2 shows efficacy. Evidence: **Low**. Likely follows Bempedoic/ApoB-lowering approach. Without revealed target, assuming small LDL reduction. Advantage: new oral entrant; Risk: unknown potency.  

- **CVI-LM001:** Current – *Mid* (Phase 2 oral PCSK9 inhibitor) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11722601/#:~:text=CVI,days%20of%20oral%20treatment%20with)); 1–3Y – *Upward* (oral delivery is big differentiator). Evidence: **High** (Phase II data ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11722601/#:~:text=match%20at%20L335%20CVI,C%2C%20compared%20with%20placebo%20cohort))). 26% LDL reduction at 300mg shown; activates AMPK reducing TG ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11722601/#:~:text=%5B11%2C24%5D%2C%20CVI,25)). Advantages: daily oral vs injections; cheap production. Disadvantages: modest LDL effect vs others; still early.  Catalysts: Phase III readout (planned for 2026).  

- **MIL86:** **Unknown**; no data found. Likely *At-risk*.  

- **SAL003:** **Unknown**; *At-risk*.  

- **Ebronucimab:** Current – *Mid* (PCSK9 Mab in China); 1–3Y – *Upward (stable)* as a local PCSK9 option. Evidence: **High** (Chinese Phase III: ~60% LDL drop ([www.sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S1043661824002858#:~:text=%2895%E2%80%AF%25CI%29%20in%20LDL,associated%20AEs))). Key diff: Full human mAb like Repatha; already proven efficacious in Chinese patients. Risk: Market share vs incumbents; only China.  

- **DNV001:** **Unknown**; likely discontinued/at-risk.  

- **RP910:** **Unknown**; at-risk.  

- **RBD7022:** Current – *Mid* (PCSK9 siRNA, Ribo) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11722601/#:~:text=DC371739%20and%20CVI,pharmacokinetic%20properties%20with%20once%20daily)); 1–3Y – *Upward* pending China launch (licensed to Qilu) and possible wider development. Evidence: **Medium**. Early studies in hamsters show ~42.6% LDL drop ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11722601/#:~:text=The%20hypocholesterolemic%20effect%20of%20CVI,fold%20with%20160%C2%A0mg%2Fkg%20OD%20%5B25)); Phase I done. Differentiator: fits growing inclisiran niche in China; injection Q3m. Risk: global inclisiran lead; heavy R&D cost.  

- **MWX203:** **Unknown**; at-risk.  

- **ASC41 (Gannex):** Current – *Mid/niche (NASH segment)*; 1–3Y – *Upward/Mid* if trials succeed. Evidence: **Medium** (Phase 1 positive in NASH; press releases ([www.ascletis.com](https://www.ascletis.com/news_detail/175/id/462/l/en-us.html#:~:text=,wholly%20owned%20company%20of%20Ascletis))). As THRβ agonist, expected to lower LDL and TG (class effect). Could capture NASH + dyslipidemia niche vs resmetirom. Risks: must avoid thyrotoxic side effects; competitive space starting to fill.  

- **HPG7233:** **Unknown**; at-risk.  

**Step 6 – Dyslipidemia Market Landscape (Segments):**  By drug class: Statins dominate (2024 ~$16.8B), driven by large at-risk populations ([www.databridgemarketresearch.com](https://www.databridgemarketresearch.com/reports/global-statin-market#:~:text=2032%20www,2032%20the%20market%20is%20likely)). PCSK9 (mAb/siRNA) are the fastest-growing high-end segment (~$3.1B in 2025 ([www.mordorintelligence.com](https://www.mordorintelligence.com/industry-reports/pcsk9-inhibitor-market#:~:text=Report%20www,forecast%20its%20value%20to%20reach))) – growth fueled by expanding indications and newer agents (inclisiran).  Omega-3 (prescription EPA/DHA) ~\$1.4–1.5B (2025) ([www.mordorintelligence.com](https://www.mordorintelligence.com/industry-reports/omega-3-prescription-drugs-market#:~:text=Drugs%20Market%20%282025%20,in%202025%20and%20is%20on)), driven by REDUCE-IT outcomes.  Other segments: Ezetimibe/fibrates are modest (generics), bempedoic growing (expected ~$1B+ by 2030) on patients intolerant of statins.  Main players: Big statin producers (Pfizer, MSD, AstraZeneca) and generics; Amgen/Sanofi (PCSK9 mAbs); Novartis (inclisiran); Sanofi/Amarin (icosapent); Esperion (bempedoic); Regeneron (evinacumab). Growth drivers: aging populace, obesity/diabetes epidemics, and intensified LDL targets.  Constraints: patent cliffs (many statins generic), payer cost pressures (especially for PCSK9), guideline plateau in statin use.  See table below.  

| **Segment**               | **Market Value**    | **Growth Drivers**                    | **Key Players**                 | **Sources**            |
|---------------------------|---------------------|---------------------------------------|---------------------------------|------------------------|
| **Statins (HMG-CoA inhibitors)** | ~$16.8 B (2024) ([www.databridgemarketresearch.com](https://www.databridgemarketresearch.com/reports/global-statin-market#:~:text=2032%20www,2032%20the%20market%20is%20likely)) | High prevalence dyslipidemia, generic availability, guideline use | Pfizer, MSD, AZ, generics    | ([www.databridgemarketresearch.com](https://www.databridgemarketresearch.com/reports/global-statin-market#:~:text=2032%20www,2032%20the%20market%20is%20likely))           |
| **PCSK9 inhibitors (mAb)**     | ~$3.1 B (2025) ([www.mordorintelligence.com](https://www.mordorintelligence.com/industry-reports/pcsk9-inhibitor-market#:~:text=Report%20www,forecast%20its%20value%20to%20reach)) | Unmet needs in very-high-risk, guideline expansions | Amgen (Repatha), Sanofi (Praluent) | ([www.mordorintelligence.com](https://www.mordorintelligence.com/industry-reports/pcsk9-inhibitor-market#:~:text=Report%20www,forecast%20its%20value%20to%20reach))        |
| **PCSK9 inhibitors (siRNA)**   | Included above    | Infrequent dosing appeal; newer approvals | Novartis (inclisiran), Ribo Life (RBD7022) | Company data         |
| **Ezetimibe**            | ~$0.5–1 B (est.)   | Add-on to statin; generic availability | Merck (Zetia)                     | Industry reports       |
| **Fibrates**             | <$0.5 B            | Residual hypertriglyceridemia          | AbbVie (Trilipix), Mylan         | Approx. generic sales  |
| **Omega-3 (Rx)**         | ~$1.5 B (2025) ([www.mordorintelligence.com](https://www.mordorintelligence.com/industry-reports/omega-3-prescription-drugs-market#:~:text=Drugs%20Market%20%282025%20,in%202025%20and%20is%20on)) | TG-lowering in high-risk pts (REDUCE-IT); aging population | Amarin (Vascepa), GSK (Lovaza)  | ([www.mordorintelligence.com](https://www.mordorintelligence.com/industry-reports/omega-3-prescription-drugs-market#:~:text=Drugs%20Market%20%282025%20,in%202025%20and%20is%20on))           |
| **Bempedoic acid**       | ~$0.5–1 B (est.)   | Statin intolerance segment; pending outcome data | Esperion                          | Latest market reports  |
| **ANGPTL3 inhibitors**   | ~$0.1 B            | HoFH, HeFH niche (evinacumab)          | Regeneron (Evkeeza), Hengrui (SHR-1918) | Niche orphan market |
| **ApoC3 inhibitors**     | <$0.1 B            | Severe HTG niche                       | Ionis/Akcea (volanesorsen), Rona (RN0361)  | Early phase         |
  
**Part B – Evidence Appendix:** See below categorized sources for all statements above.  

**Guidelines/Consensus:** ACC/AHA (2018) and ESC (2019, 2025 update) cholesterol guidelines ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7403606/#:~:text=%28LDL,C%20levels%20by%20%E2%89%A550)) ([academic.oup.com](https://academic.oup.com/eurheartj/article/41/1/111/5556353#:~:text=match%20at%20L2779%20ezetimibe%20should,273)). Shen/China (2023) available (e.g., **China Lipids Guidelines**).  
**Regulatory/Labels:** FDA labels for statins, PCSK9 inhibitors, inclisiran; EU/NICE guidances (inclisiran).  
**Key Trials:** IMPROVE-IT (ezetimibe) ([academic.oup.com](https://academic.oup.com/eurheartj/article/41/1/111/5556353#:~:text=match%20at%20L2779%20ezetimibe%20should,273)), FOURIER/ODYSSEY (PCSK9) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7403606/#:~:text=%E2%89%A570%20mg%2FdL%28%E2%89%A51,2018%20list%20prices)), REDUCE-IT (EPA) ([academic.oup.com](https://academic.oup.com/eurheartj/article/41/1/111/5556353#:~:text=match%20at%20L2779%20ezetimibe%20should,273)), CLEAR outcomes (bempedoic). Hengrui JAMA Cardiol (SHR-1918) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41499141/#:~:text=Results%3A%20A%20total%20of%2026,and%20included%20pain%20and)), Rona AHA abstract (RN0361) ([www.ronatherapeutics.com](https://www.ronatherapeutics.com/news/39#:~:text=The%20randomized%2C%20placebo,HbA1c%20were%20observed%20versus%20placebo)), Innovent/PubMed (Ebronucimab) ([www.sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S1043661824002858#:~:text=%2895%E2%80%AF%25CI%29%20in%20LDL,associated%20AEs)), DDT&T (BGT-002) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/40093645/#:~:text=with%20a%20dose,serious%20adverse%20events%20were%20observed)), Athl Plas. 2024 (CVI-LM001 review) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11722601/#:~:text=The%20hypocholesterolemic%20effect%20of%20CVI,fold%20with%20160%C2%A0mg%2Fkg%20OD%20%5B25)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11722601/#:~:text=CVI,C%2C%20compared%20with%20placebo%20cohort)).  
**Market Research:** 24LifeSciences 2024 Dyslipidemia report ([www.24lifesciences.com](https://www.24lifesciences.com/dyslipidemia-drugs-market-9113#:~:text=The%20global%20dyslipidemia%20drugs%20market,during%20the%20forecast%20period)), Statin market (Databridge) ([www.databridgemarketresearch.com](https://www.databridgemarketresearch.com/reports/global-statin-market#:~:text=2032%20www,2032%20the%20market%20is%20likely)), Mordor/IMARC on PCSK9 ([www.mordorintelligence.com](https://www.mordorintelligence.com/industry-reports/pcsk9-inhibitor-market#:~:text=Report%20www,forecast%20its%20value%20to%20reach)), Omega-3 market (Mordor) ([www.mordorintelligence.com](https://www.mordorintelligence.com/industry-reports/omega-3-prescription-drugs-market#:~:text=Drugs%20Market%20%282025%20,in%202025%20and%20is%20on)).  
**Company Disclosures:** Rona Ther/RND press (RN0361) ([www.ronatherapeutics.com](https://www.ronatherapeutics.com/news/39#:~:text=The%20randomized%2C%20placebo,HbA1c%20were%20observed%20versus%20placebo)); Innovent poster (Ebronucimab) ([www.sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S1043661824002858#:~:text=%2895%E2%80%AF%25CI%29%20in%20LDL,associated%20AEs)); Ribo Life press (license) ([www.ribolia.com](https://www.ribolia.com/En/pipeline#:~:text=,also%20under%20investigation%20as%20a)); Gannex press (ASC41) ([www.ascletis.com](https://www.ascletis.com/news_detail/175/id/462/l/en-us.html#:~:text=,wholly%20owned%20company%20of%20Ascletis)).  

